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The aim of this study is to investigate the antibacterial, antifungal activity of the new six membered 4-(4-bromophenyl)-
4-hydroxy-2.6-diphenylcyclohexane-1.3-diyl)bis(4-bromophenyl)methanone and known (E)-1-(4-bromophenyl)-3-
phenylprop-2-en-1-one. The investigated products exhibit promising activities. 
Keywords: Antimicrobial, antibacterial, aromatic ketone, cyclohexanol 
The aromatic ketones are effective compounds in 
organic synthesis and have important significance for 
synthesis of different practical compounds1-10, which 
have physiological activity. Due to the their different 
functionality these compounds confer biological 
activities, such as antimicrobial, antibacterial, 
antifungal, anticancer, antiviral, anti-inflammatory, 
antihyperglycemic11-21. 
Taking into account of their pharmaceutical 
actuality the 1,2,3,4,5-pentasubstituted cyclohexanol 
and its forming chalcone against S. aureus, E. coli, 





Materials and instrumentation 
All the chemicals were obtained from commercial 
sources (Aldrich) and used as received. NMR 
experiments have been performed on a BRUKER FT 
NMR spectrometer (UltraShieldTM Magnet) 
AVANCE 300 (300.130 MHz for 1H and 75.468 MHz 
for 13C) with a BVT 3200 variable temperature unit in 
5 mm sample tubes using Bruker Standard software 
(TopSpin 3.1). The 1H and 13C chemical shifts were 
referenced to internal tetramethylsilane (TMS); the 
experimental parameters for 1H: digital resolution = 
0.23 Hz, SWH = 7530 Hz, TD = 32 K, SI = 16 K, 90° 
pulse-length = 10 μs, PL1 = 3 dB, ns-= 1, ds= 0, d1 =1 
s; for 13C: digital resolution = 0.27 Hz, SWH = 17985 
Hz, TD = 64 K, SI = 32 K, 90° pulse-length = 9 μs, 
PL1 = 1.5 dB, ns= 100, ds= 2, d1= 3 s (Figure S1-S9, 
Supplementary Information). NMR-grade acetone-d6 
were used for the solutions of 1 and 2. 
Electrospray mass spectra of new 2 was run with 
an ion-trap instrument (Esquire 6000 Ion Trap Mass 
Spectrometer) equipped with an electrospray (ESI) 
ion source. For electrospray ionization, the drying 
gas and flow rate were optimized according to  
the particular sample with 35 psi nebulizer  
pressure. Scanning was performed from m/z 100 to 
1200 in methanol solution. The compounds were  
observed in the positive mode (capillary voltage = 
80–105 V). 
The purity of the synthesized compounds were 
confirmed by thin-layer chromatography (TLC) on 
commercial aluminum-backed plates of silica gel (60 
F254), iodine vapor was used as visualizing agent, 
eluent- 5:2 hexane/ethyl acetate.  
Melting points were measured on an 
Electrothermal 9100 apparatus without correction. 
 
Synthesis 
A mixture of 4-bromoacetophenone (1.99 g, 0.01 
mol) and benzaldehyde (1.06 g, 0.01 mol) in 20 mL 
ethanol, 0.5 and 5 mL of 10-60 % sodium (or 
potassium) hydroxide solution was added and stirred 
at room temperature for 3 hours. The forming 
precipitate was collected by filtration and 
recrystallized in ethanol. In the presence of 0.5 and 
5 mL of 10-40% sodium or potassium hydroxide 
solution a white compound 1 was obtained which had 
been described in the literature (yield 67-90%); in the 
presence of 5 mL of 50 and 60% sodium or potassium 




hydroxide solution a new pale pink compound 2, yield 
26-37%; m.p.180-183°C. 
1H NMR of compound 2 (acetone-d6, 300 MHz): δ 
1.91 and 3.43 (d-d and t, 2J=12.4, 3J=4.3, 3J=7.6, 2H, 
CH2), 4.19 (m, 1H, CH), 4.53 (t, 3J=4.6, 1H, CH), 
4.31 (d-d, 3J=12.5, 3J=7.6,), 4.91 (d, 1H, OH), 5.13 (d, 
3J=12.5, 1H, CH), 6.85-7.71 (m, 22H, CHarom.); 
13C NMR of compound 2 (acetone-d6, 75 MHz): δ 
38.7, 40.8, 44.9, 51.3, 52.1, 120.0, 126.1, 126.3, 
126.5, 126.6, 127.5, 128.4, 128.5, 128.6, 128.7, 129.8, 
131.5, 132.6, 143.2, 147.7, 200.1, 204.6,; ESI-MS: 
m/z [M+H]+ 773, 692, 553, 500, 411, 361, 306. 
 
Antibacterial and antifungal testing 
Compounds 1 and 2 were evaluated for their 
in vitro antibacterial, antifungal activities by the agar 
disc-diffusion and diffusion zone method.21 Stock 
solutions of test compounds were diluted in dimethyl 
sulfoxide (DMSO) to give a final concentration of 10 
mg/mL. The DMSO alone was used as a control and it 
was revealed, that solvent doesn't influence to 
antibacterial-antifungal properties (zone of inhibition 
was 1-1.5 mm). The plates with bacterial suspensions 
and disk of investigated compounds were incubated at 
37°C, at 24 hours for the bacteria and fungi. After 
incubation, growth was surveyed by measuring the 
diameter of the growth inhibition zones.  
In this work used differential microorganisms and 
culture media from the company “Liofilchem” (Italy): 
Staphylococcus aureus (ATCC 25923), Escherichia 
coli (ATCC 25922), and KES (Klebsiella, 
Enterobacter, Serratia), Aspergillus niger (the 
isolates from the different foods and water). 
 
Results and Discussion 
In our previous work is reported about the 
synthesis methods, reaction mechanism and 3D 
structure determination of new polysubstituted 
cyclohexanol by NMR and quantum-chemical 
methods.10 The compound 2 was characterized by 1H, 
13C NMR spectroscopy and ESI-MS methods (Figure 
S1-9, Supplementary Information). Condensation of 
4-bromoacetophenone with benzaldehyde can lead to 
formation of two different compounds, as given in 
Scheme I. 
Possible formation mechanism of 2 at the presence 
of a base catalyst is given in Scheme II. 
Our goal in this work were to examine of 
antimicrobial and antifungal activity of (E)-1-(4-
bromophenyl)-3-phenylprop-2-en-1-one (1) and new 
4-(4-bromophenyl)-4-hydroxy-2.6-
diphenylcyclohexane-1.3-diyl)bis(4-bro-
mophenyl)methanone (2). The in vitro antibacterial 
activities of compounds 1, 2 were evaluated against 
gram-positive and gram-negative bacteria and fungi 
using the cultures of different standard 
microorganisms: Staphylococcus aureus, 
Escherichia coli, KES (Klebsiella, Enterobacter, 
Serratia), and Aspergillus niger (the isolates from 
the different foods and water). Our investigations 
demonstrated that, compound 2 in minimal 




Scheme I — Synthesis of the chalcone 1 and its cyclohexenol derivative 2 




than 1 against of KES (Klebsiella, Enterobacter, 
Serratia), that can be probably caused by the 
presence of five aromatic ring and three bromine 
atom in the molecule. The results demonstrated that, 
compound 2 had good growth-inhibiting activity 
against of Escherichia coli. But compound 1 in 
minimal concentration exhibited the best growth-
inhibiting effects against of Staphylococcus aureus, 
which can be explained by the presence of 
unsaturated bond, aromatic ring and bromine atom in 
the molecule 1. These compounds demonstrate also 
antifungal activities in minimal concentration. The 
results are shown in Table I. 
 
Conclusions 
In presented work we demonstrated one-pot 
practical simple method, which provides the fast and 
synchronous preparation of two practical important 
compounds: ((E)-1-(4-bromophenyl)-3-phenylprop-2-
en-1-one (1) and 4-(4-bromophenyl)-4-hydroxy-2.6-
diphenylcyclohexane-1.3-diyl)bis(4-bromophenyl)-
methanone) (2) with good yields. This allows to make 
fast pharmacological activities test of these novel 
polysubstituted cyclohexanol derivatives and known 
chalcone. The simplicity, minimal concentration 
effect, inexpensive starting materials, easy setup, 









Scheme II — Formation mechanism of the compound 2 at the presence of base catalyst 
  
Table I — Antibacterial, antifungal activity of 1 and 2 in DMSO 
solution (10 mg/mL) 
(diffusion zone method and disc-diffusion method) 
Compd Microorganisms Antimicrobial activity (zone of 





1 S. aureus 37 24 
KES 18 12 
Escherichia coli 28 16 
Aspergillus 11 7 
2 S. aureus 30 16 
KES  42 24 
Escherichia coli 32 21 
Aspergillus 16 9 
 





1 Dhar D N, The Chemistry of Chalcones and Related 
Compounds (Wiley, New York), pp.285 (1981). 
2 Mamedov I G, Bayramov M R, Mamedova Y V & 
Maharramov A M, Magn Reson Chem, 53 (2015) 147. 
3 Mamedov I G, Bayramov M R, Mamedova Y V & 
Maharramov A M, Magn Reson Chem, 51 (2013) 600. 
4 Mamedov I G, Bayramov M R, Mamedova Y V & 
Maharramov A M, Magn Reson Chem, 51 (2013) 234. 
5 Mamedov I G, Bayramov M R, Salamova A E & 
Maharramov A M, İndian J Chem, 54B (2015) 1518. 
6 Mamedov I G, Maharramov A M, Bayramov M R & 
Mamedova Y V, Russ J Physic Chem A, 84 (2010) 2182. 
7 Mamedov I G, Eichhoff U, Maharramov A M, Bayramov M 
R & Mamedova Y V, Cent Eur J Chem, 10 (2012) 241. 
8 Yadigarov R R, Khalilov A N, Mamedov I G, Nagiev F N, 
Magerramov A M & Allakhverdiev M A, Russ J Org Chem, 
45 (2009) 1856. 
9 Abdelhamid A A, Mohamed S K, Maharramov A M, 
Khalilov A N & Allahverdiev M A, J Saudi Chem Soc, 18 
(2014) 474. 
10 Mamedov I G, Abbasoglu R, Bayramov M R & Maharramov 
A, Magn. Reson. Chem. 54 (2016) 315. 
11 Nowakowska Z, Kedzia B & Schroeder G, Eur J Med Chem, 
43 (2008) 707. 
12 Mishra N, Arora P, Kumar B, Mishra L C, Bhattacharya A, 
Awasthi S K & Bhasin V K, Eur J Med Chem, 43 (2008) 1530.  
13 Dong X, Liu T, Yan J, Wu P, Chen J & Hu Y, J Bioorg Med 
Chem, 17 (2009) 716. 
14 Katade S, Phalgune U, Biswas S, Wakhardar R & 
Deshpandey N, Indian J Chem, 47B (2008) 927. 
15 Khatib S, Nerya O, Musa R, Shmuel M, Tamir S & Vaya J, 
Bioorg Med Chem, 13 (2005) 433. 
16 Sharma V & Sharma K V, Elec J Chem, 7 (2010) 203. 
17 Hsieh H K, Tsao L T, Wang J P & Lin C N, J Pharm 
Pharmacol, 52 (2000) 163. 
18 Ram V J, Saxena A S, Srivastava S & Chandra S, Bioorg 
Med Chem Lett, 10 (2000) 2159. 
19 Mamedov I G, Mamedova Y V, Khrustalev V N, Bayramov 
M R & Maharramov A M, Indian J Chem, 56B (2017) 192. 
20 Mamedov I G, Farzaliyeva A E, Mamedova Y V, Hasanova 
N N, Bayramov M R & Maharramov A M, Indian J Chem, 
57B (2018) 1310. 
21 Approved Standard Document M-7A. NCCLS; Villanova, 
PA. National Committee for Clinical Laboratory Standards. 
USA (1985). 
 
